NDUFS7
ENSG00000115286
Target class
Enzyme
Chromosome
19
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- NDUFS7
- Gene name
- NADH:ubiquinone oxidoreductase core subunit S7
- Gene symbol
- NDUFS7
- Protein name
- NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial (EC 7.1.1.2) (Complex I-20kD) (CI-20kD) (NADH-ubiquinone oxidoreductase 20 kDa subunit) (PSST subunit)
- PSST
- FLJ46880
- FLJ45860
- CI-20
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase core subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Highest tissue expression
- 88.05
- Tissue specificity (Gini)
- 0.167
- Tissue specificity (tau)
- 0.551
- KEGG gene identifiers
- hsa:374291
- Protein interaction confidence
- 0.924558
- Protein interaction partners
- 113
- R-HSA-611105
- R-HSA-6799198
- End position
- 1395590
- Start position
- 1383527
- Chromosome
- 19
- Strand
- Forward
- Mitochondrion inner membrane
- Peripheral membrane protein
- Matrix side .
Publication evidence
- PubMed 12611891
- Tissue specificity (tau)
- 0.551402
- Expression inequality (Gini)
- 0.166841
Expression in transcripts per million
- Muscle - Skeletal
- 88.05
- Brain - Cerebellar Hemisphere
- 84.57
- Brain - Cerebellum
- 83.99
- Testis
- 68.19
- Heart - Left Ventricle
- 64.3
Expression in transcripts per million
- Muscle - Skeletal88.05
- Brain - Cerebellar Hemisphere84.57
- Brain - Cerebellum83.99
- Testis68.19
- Heart - Left Ventricle64.3
- Brain - Spinal cord (cervical c-1)58.73
- Heart - Atrial Appendage55.69
- Pituitary48.33
- Brain - Frontal Cortex (BA9)45.66
- Colon - Sigmoid45.51
- Nerve - Tibial45.06
- Brain - Cortex42.51
- Esophagus - Mucosa41.85
- Brain - Substantia nigra41.63
- Uterus41.25
- Esophagus - Gastroesophageal Junction39.8
- Thyroid39.67
- Esophagus - Muscularis39.58
- Fallopian Tube39.54
- Vagina39.39
- Cells - EBV-transformed lymphocytes39.29
- Colon - Transverse39.27
- Brain - Hypothalamus38.58
- Brain - Nucleus accumbens (basal ganglia)38.08
- Ovary37.89
And 29 more, listed on the interactive page.
- GO:0006120
- GO:0032981
- GO:0005739
- GO:0005743
- GO:0005759
- GO:0045271
- GO:0003954
- GO:0005515
- GO:0008137
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor